Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex

New mutations raise specter of ‘immune escape’

(2021) Kai Kupferschmidt   SCIENCE

Viral evolution may herald new pandemic phase

(2021) Kai Kupferschmidt   SCIENCE

Fast-spreading U.K. virus variant raises alarms

(2021) Kai Kupferschmidt   SCIENCE

Maturation and persistence of the anti-SARS-CoV-2 memory B cell response

(2021) Aurélien Sokal et al.   CELL

SARS-CoV-2 Viral Variants—Tackling a Moving Target

(2021) John R. Mascola et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

SARS-CoV-2 variants and ending the COVID-19 pandemic

(2021) Arnaud Fontanet et al.   LANCET

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

(2021) Pengfei Wang et al.   NATURE

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

(2021) Constantinos Kurt Wibmer et al.   NATURE MEDICINE

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report

(2021) Kai Wu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients

(2021) Juanjie Tang et al.   Nature Communications

Longitudinal antibody repertoire in “mild” versus “severe” COVID-19 patients reveals immune markers associated with disease severity and resolution

(2021) Supriya Ravichandran et al.   Science Advances

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera

(2021) Alona Kuzmina et al.   Cell Host & Microbe

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

(2021) Pengfei Wang et al.   Cell Host & Microbe

SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities

(2021) Arturo Casadevall et al.   JOURNAL OF CLINICAL INVESTIGATION

Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses

(2021) Kevin O. Saunders et al.   NATURE

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

(2021) David S. Khoury et al.   NATURE MEDICINE

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

(2021) Joseph E. Ebinger et al.   NATURE MEDICINE

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants

(2021) Yang Liu et al.   NEW ENGLAND JOURNAL OF MEDICINE

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

(2021) Leonidas Stamatatos et al.   SCIENCE

Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

(2021) Catherine J. Reynolds et al.   SCIENCE

The emerging plasticity of SARS-CoV-2

(2021) Kevin D. McCormick et al.   SCIENCE

Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination

(2021) Rishi R. Goel et al.   Science Immunology

Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status

(2021) David W. Eyre et al.   CLINICAL MICROBIOLOGY AND INFECTION

Marked Increase in Avidity of SARS-CoV-2 Antibodies 7–8 Months After Infection Is Not Diminished in Old Age

(2021) Daniel Pichler et al.   JOURNAL OF INFECTIOUS DISEASES

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

(2021) Emma C Wall et al.   LANCET

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

(2021) Jianying Liu et al.   NATURE

Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection

(2021) Allison J. Greaney et al.   Science Translational Medicine

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies

(2021) Allison J. Greaney et al.   Nature Communications

Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern

(2021) Juanjie Tang et al.   iScience

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

(2021) Rishi R. Goel et al.   SCIENCE

Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design

(2020) Surender Khurana et al.   Cell Host & Microbe

Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits

(2020) Supriya Ravichandran et al.   Science Translational Medicine

Differential human antibody repertoires following Zika infection and the implications for serodiagnostics and disease outcome

(2019) Supriya Ravichandran et al.   Nature Communications

Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial

(2019) Richard T Davey et al.   Lancet Respiratory Medicine

H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine

(2014) Surender Khurana et al.   VACCINE

Oligomeric Recombinant H5 HA1 Vaccine Produced in Bacteria Protects Ferrets from Homologous and Heterologous Wild-Type H5N1 Influenza Challenge and Controls Viral Loads Better than Subunit H5N1 Vaccine by Eliciting High-Affinity Antibodies

(2012) S. Verma et al.   JOURNAL OF VIROLOGY

AID Activity in B Cells Strongly Correlates with Polyclonal Antibody Affinity Maturation in-vivo Following Pandemic 2009-H1N1 Vaccination in Humans

(2012) Surender Khurana et al.   PLoS Pathogens

MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines

(2011) S. Khurana et al.   Science Translational Medicine